The aforementioned findings suggest that in the alternative pathway, ACE2 inhibits the activation of the RAS and thus inhibits the JAK2/STAT3 pathway, reducing the inflammatory response and renal injury of DKD. Here, JAK2 is linked to diabetic kidney disease.